Moleculin Biotech (FRA:MOL0) Cyclically Adjusted FCF per Share: €-50,528.99 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MOL0 Moleculin Biotech Inc FRA:MOL0
30 GF Score
Price €161.25
! 1 Warning Sign
View Full Analysis

What is Moleculin Biotech Cyclically Adjusted FCF per Share?

Moleculin Biotech FRA:MOL0 30 Cyclically Adjusted FCF per Share is €-50,528.99 as of Mar. 2026. GuruFocus rates FRA:MOL0 with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Moleculin Biotech's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-1.282. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-50,528.99 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-30), Moleculin Biotech's current stock price is €161.25. Moleculin Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-50,528.99. Moleculin Biotech's Cyclically Adjusted Price-to-FCF of today is .


Moleculin Biotech  (FRA:MOL0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Moleculin Biotech Cyclically Adjusted FCF per Share Related Terms


Moleculin Biotech Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Moleculin Biotech's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech Cyclically Adjusted FCF per Share Chart

Moleculin Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -34,619.55

Moleculin Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -8,888.34 -34,619.55 -50,528.99

FRA:MOL0 vs AKTX, INTI, TPST: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Moleculin Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moleculin Biotech Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moleculin Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Moleculin Biotech's Cyclically Adjusted Price-to-FCF falls into.


FRA:MOL0
30GF Score
Moleculin Biotech Inc FRA:MOL0
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moleculin Biotech Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Moleculin Biotech's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.282/330.2130*330.2130
=-1.282

Current CPI (Mar. 2026) = 330.2130.

Moleculin Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -301.500 241.018 -413.078
201609 -169.400 241.428 -231.697
201612 -221.600 241.432 -303.088
201703 -216.833 243.801 -293.687
201706 -214.875 244.955 -289.663
201709 -150.222 246.819 -200.978
201712 -224.444 246.524 -300.637
201803 -228.200 249.554 -301.957
201806 -247.333 251.989 -324.112
201809 -222.417 252.439 -290.942
201812 -236.167 251.233 -310.411
201903 -262.923 254.202 -341.542
201906 -249.947 256.143 -322.225
201909 -151.400 256.759 -194.713
201912 -210.900 256.974 -271.008
202003 -178.727 258.115 -228.650
202006 -169.115 257.797 -216.620
202009 -179.630 260.280 -227.894
202012 -89.000 260.474 -112.829
202103 -52.483 264.877 -65.429
202106 -74.053 271.696 -90.002
202109 -47.961 274.310 -57.735
202112 -49.579 278.802 -58.721
202203 -57.474 287.504 -66.012
202206 -100.355 296.311 -111.837
202209 -100.697 296.808 -112.030
202212 -91.333 296.797 -101.616
202303 -72.987 301.836 -79.849
202306 -59.886 305.109 -64.813
202309 -89.557 307.789 -96.082
202312 -55.444 306.746 -59.686
202403 -62.424 312.332 -65.998
202406 -54.186 314.175 -56.952
202409 -36.966 315.301 -38.714
202412 -24.030 315.605 -25.142
202503 -11.289 319.799 -11.657
202506 -7.794 322.561 -7.979
202509 -4.125 324.800 -4.194
202512 -1.433 324.054 -1.460
202603 -1.282 330.213 -1.282

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-50,528.99 mean?
Moleculin Biotech (FRA:MOL0) has a Cyclically Adjusted FCF per Share of €-50,528.99 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Moleculin Biotech and its competitors.
Is Moleculin Biotech's Cyclically Adjusted FCF per Share too high?
Moleculin Biotech's current Cyclically Adjusted FCF per Share is €-50,528.99. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's Cyclically Adjusted FCF per Share compare to AKTX and INTI?
Moleculin Biotech's Cyclically Adjusted FCF per Share of €-50,528.99 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Moleculin Biotech and its competitors. Moleculin Biotech's current Cyclically Adjusted FCF per Share is €-50,528.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (FRA:MOL0) has a current Cyclically Adjusted FCF per Share of €-50,528.99. The current Cyclically Adjusted FCF per Share is €-50,528.99. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Moleculin Biotech (FRA:MOL0), the current Cyclically Adjusted FCF per Share is €-50,528.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moleculin Biotech Business Description

Other Exchanges MBRX:USA0K2H:UK
Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score

Get the complete analysis for FRA:MOL0

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€161.25
Price